Ono Pharma submits supplemental application in Japan to expand the Use of Opdivo to treat unresectable anaplastic thyroid cancer

Ono Pharmaceutical has submitted a critical supplemental application in Japan to broaden the use of its blockbuster immunotherapy, Opdivo (nivolumab), specifically for treating unresectable anaplastic thyroid cancer (ATC). This move, based on compelling Phase 2 data from the investigator-initiated NAVIGATION study, which paired Opdivo with Eisai's Lenvima, signals a potential breakthrough against one of the most aggressive and rapidly fatal forms of cancer, offering a new lifeline where current options are severely limited. The combination therapy achieved a 47.6% objective response rate, meeting its primary endpoint with a manageable safety profile. The stakes are exceptionally high for patients facing ATC, a rare but devastating malignancy with a median survival often measured in mere months. Existing treatments, including surgery, radiation, and chemotherapy, frequently prove ineffective, especially in unresectable cases. Ono's application leverages Opdivo mechanism as a PD-1 immune checkpoint inhibitor, designed to unleash the body's own immune system against cancer cells, combined with Lenvima targeted action against tumor growth and angiogenesis. This dual-action approach represents a significant evolution in tackling cancers that have historically resisted conventional therapies, underscored by Opdivo recent orphan drug designation and priority review status by Japan Ministry of Health, Labour and Welfare. With the application now under review by the Pharmaceuticals and Medical Devices Agency (PMDA), the focus shifts to the timeline for a potential approval. Given the orphan drug and priority review designations, Japan regulatory bodies are expected to expedite evaluation, potentially shortening the typical drug approval process. If approved, this combination therapy could redefine the standard of care for unresectable anaplastic thyroid cancer, opening doors for patients who previously had few, if any, viable treatment paths. Healthcare providers and patients will be closely watching for a decision that could mark a pivotal advancement in the fight against this relentless disease.